Endometrial Cancer

ERT poses little recurrence risk for women treated for early-stage disease

Published in Women's Health Weekly, March 4th, 2004

In a study conducted over a 5-year period with more than 1,200 women with early-stage endometrial cancer, a team of physicians found that estrogen replacement therapy was associated with a low incidence of endometrial cancer recurrence.

In the largest prospective, randomized, controlled trial to date, 618 women were selected to receive estrogen replacement therapy (ERT) following surgery for stage I or II endometrial cancer and 618 women were selected randomly to receive a placebo. Both groups were treated for 3 years, with an additional 2 years of follow-up. Due to an enrollment drop in the study following the June 2002 publication of the Women's Health Initiative...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry